CEL-SCI (CVM) announced that a Breakthrough Medicine Designation application has been filed with the Saudi Food and Drug Authority for Multikine in Saudi Arabia. The application was submitted by a premier Saudi pharma company with which CEL-SCI has signed a memorandum of understanding for the commercialization of Multikine.The response time to the application is approximately 60 days. If granted, the designation would immediately make Multikine available for patient access and reimbursement in Saudi Arabia.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CVM: